I must have that wrong. Why would they do a trial in a cancer so...

First 144 Last

Share
Profile

Follow
Taureanbull

3,733 Posts.

8214

16/04/25

12:18

Post #: 78711765
Share

Originally posted by Taureanbull ↑

our next trial?

Chronic Neutrophilic Leukemia (CNL) is an extremely rare myeloproliferative disorder characterized by an overproduction of neutrophils. Given its rarity, there is limited publicly available data on the exact market size for CNL treatments. However, information on the broader market for myeloproliferative disorders and rare hematological diseases can provide some context:

1. **Prevalence**: CNL is very rare, with only around 200 cases reported in the medical literature. This rarity significantly impacts the market size, making it much smaller compared to other more common types of leukemia or blood disorders.

2. **Treatment Options**: The market size is predominantly determined by the available treatment options, which may include targeted therapies like ruxolitinib (Jakafi), hydroxyurea, interferon-alpha, or other supportive care measures. New treatments could be in development through clinical trials.

3. **Research and Development**: The rarity of CNL means that pharmaceutical companies may focus more on research and development efforts within the broader category of myeloproliferative neoplasms (MPNs), which could indirectly address CNL.

4. **Market Characteristics**: For ultra-rare conditions like CNL, treatment markets often rely heavily on novel therapeutic agents, orphan drug designations, and niche pharmaceutical companies specializing in rare diseases.

5. **Economic Factors**: The costs associated with developing treatments for rare diseases are significant, which can influence the market size and pricing strategies for any approved therapies.

Overall, while the precise market size for CNL is not well-defined due to its rarity, it is part of a broader focus area in hematology that targets rare blood cancers and conditions. For exact figures or forecasts, consulting specialized market research reports from life sciences consulting firms or databases might be necessary.

Expand

I must have that wrong. Why would they do a trial in a cancer so rare they couldn’t find and patients.

Did any body catch the name of that cancer their evaluating for future trial prospects.

IMU Price at posting: 2.7¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

NVO

Novo flags antimony and gold in the Pilbara – but does it need to step back?

AL3

AML3D opens new facility in Ohio as US Defence strategy bears fruit

PV1

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

First 144 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.3¢		Change -0.001(3.85%)		Mkt cap ! $93.33M

Open	High	Low	Value	Volume
1.2¢	1.3¢	1.2¢	$75.79K	5.965M

Buyers (Bids)

No.	Vol.	Price($)
68	14874494	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.3¢	7628741	33

View Market Depth

No.	Vol.	Price($)
68	14927828	0.012
41	12299409	0.011
55	16198075	0.010
15	3474488	0.009
6	784859	0.008

Price($)	Vol.	No.
0.013	7666086	33
0.014	12061829	27
0.015	8553797	36
0.016	6578798	30
0.017	13604865	17

Last trade - 13.03pm 20/06/2025 (20 minute delay)

IMU (ASX) Chart

I must have that wrong. Why would they do a trial in a cancer so...

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Novo flags antimony and gold in the Pilbara – but does it need to step back?

AML3D opens new facility in Ohio as US Defence strategy bears fruit

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I must have that wrong. Why would they do a trial in a cancer so...

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Novo flags antimony and gold in the Pilbara – but does it need to step back?

AML3D opens new facility in Ohio as US Defence strategy bears fruit

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News